ストックスクリーナーアプリを入手
3.11
6.87%
0.20
アフターアワーズ：
3.02
-0.09
-2.89%
前日終値:
$2.91
開ける：
$2.91
24時間の取引高:
99,467
Relative Volume:
1.75
時価総額：
$1.60M
収益：
$11.51M
当期純損益:
$-54.00M
株価収益率:
-0.00437
EPS:
-711.8194
ネットキャッシュフロー:
$-23.73M
1週間 パフォーマンス:
-7.30%
1か月 パフォーマンス:
-77.09%
6か月 パフォーマンス:
-92.36%
1年 パフォーマンス:
-97.82%
1日の値動き範囲:
$2.91
$3.24
1週間の範囲:
$2.84
$3.99
52週間の値動き範囲:
$2.53
$155.91
Jaguar Health Inc Stock (JAGX) Company Profile
名前
Jaguar Health Inc
セクター
電話
415-371-8300
住所
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
3.11 | 1.50M | 11.51M | -54.00M | -23.73M | -711.82 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
Jaguar Health Inc (JAGX) 最新ニュース
Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Reven - GuruFocus
JAGX: Q1 2026 net revenue jumped 816% year-over-year, fueled by a major out-license agreement - TradingView
JAGX: Q1 2026 revenue jumped 816% year-over-year, fueled by a transformative licensing deal - TradingView
Earnings call transcript: Jaguar Health Q1 2026 revenue surges 816% By Investing.com - Investing.com Canada
Q1 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health (JAGX) Q3 2025 Earnings Transcript - AOL.com
Jaguar Health, Inc. Announces Entry Into Material Definitive Exchange Agreements With Streeterville Capital, LLC - Minichart
Jaguar Health Inc (HAM:1JA1) Stock Price, Trades & News - GuruFocus
Jaguar Health (NASDAQ: JAGX) delays 2026 meeting after Nasdaq talks - Stock Titan
JAGX Stock Price, Quote & Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health Inc stock (US47010C1053): Q1 2026 revenue surge draws volatile market reaction - AD HOC NEWS
JAGX Sees Dramatic Revenue Surge in Q1 2026 - GuruFocus
JAGX Financials: Income Statement, Balance Sheet & Cash Flow | Jaguar Health Inc - Stock Titan
Jaguar Health Reports First Quarter 2026 Financials - ACCESS Newswire
JAGX: Net revenue jumped 816% year-over-year, fueled by a major licensing deal and strategic refocus - TradingView
Jaguar Health reports Q1 2026 revenue up 816% to $20.3M, operating income $10.2M - TradingView
Jaguar Health licenses U.S. Mytesi rights in $19M Q1 deal - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jaguar Health (NASDAQ: JAGX) posts 816% Q1 2026 revenue surge - Stock Titan
JAGUAR HEALTH ($JAGX) Releases Q1 2026 Earnings - Quiver Quantitative
Jaguar Health, Inc. 1Q 2026: Revenue $20.3M, Net income $8.72M, EPS $(13.60) — 10-Q Summary - TradingView
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jaguar Health (JAGX) turns Q1 profit but flags going concern risks - Stock Titan
Jaguar (JAGX) Q4 2025 Earnings Transcript - The Globe and Mail
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference - ACCESS Newswire
Jaguar Health: May 26 Q1 webcast, CEO at May 28 Lytham event - Stock Titan
Jaguar Health, Inc. Announces Series Q Preferred Stock Exchange Agreements and Related SEC Filing Details - Minichart
Jaguar Animal Health Issues Series Q Preferred Stock - TipRanks
Jaguar Health Exchanges Series Q Preferred to Cut $22.7 Million in Royalty Obligations - TradingView
Jaguar Health (NASDAQ: JAGX) cuts $22.7M royalties via new Series Q preferred - Stock Titan
Jaguar Health (JAGX) Initiates Key Pediatric Clinical Trial Phas - GuruFocus
Jaguar Health | DEFA14A: Others - Moomoo
Jaguar Health’s crofelemer trial advances for rare pediatric disease - Investing.com
Jaguar Health’s crofelemer trial advances for rare pediatric disease By Investing.com - Investing.com India
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer - Yahoo Finance
Jaguar Health stock surges on FDA breakthrough discussions for rare disease therapy - MSN
Jaguar Health Delays Quarterly Filing Briefly - TipRanks
Jaguar Health (NASDAQ: JAGX) delays Q1 2026 10-Q, cites subsequent events - Stock Titan
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health, Inc.Common Stock (NQ: JAGX - FinancialContent
Jaguar Health stock (US47010C1053): volatile biotech name in focus after latest financing moves - AD HOC NEWS
About Us | Cabling Installation & MaintenanceJaguar Health, Inc.Common Stock (Nasdaq:JAGX) Stock Quote - FinancialContent
JAGX Q1'26 Earnings: EPS estimate is (71.40) USD - TradingView
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - ACCESS Newswire
Jaguar Health Inc (HAM:1JA1) Valuation - GuruFocus
Jaguar Health (HAM:1JA1) Net Intangibles Purchase And Sale : €0.00 Mil (TTM As of Dec. 2025) - GuruFocus
Jaguar Health Inc Stock Historical Valuations | HAM:1JA1 - GuruFocus
Who's Buying or Selling Jaguar Health Inc (HAM:1JA1) Stock Today? - GuruFocus
Jaguar Health Inc (HAM:1JA1) DCF Valuation - GuruFocus
Jaguar Health Inc Stock Baskets | HAM:1JA1 - GuruFocus
Q3 2024 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Inc (JAGX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):